EP 0865280 A1 19980923 - ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
Title (en)
ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
Title (de)
ALPHA 1a ADRENERGISCHE REZEPTORANTAGONISTEN
Title (fr)
ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
Publication
Application
Priority
- GB 9603423 A 19960219
- US 9618321 W 19961112
- US 676595 P 19951115
Abstract (en)
[origin: WO9717967A1] This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1a adrenergic receptor antagonists. One application of these componds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
IPC 1-7
IPC 8 full level
C07D 241/24 (2006.01); A61K 31/445 (2006.01); A61K 31/451 (2006.01); A61K 31/495 (2006.01); A61P 13/02 (2006.01); A61P 15/00 (2006.01); A61P 43/00 (2006.01); C07D 211/60 (2006.01); C07D 211/64 (2006.01)
CPC (source: EP)
A61K 31/451 (2013.01); A61K 31/495 (2013.01); A61P 13/02 (2017.12); A61P 15/00 (2017.12); A61P 43/00 (2017.12)
Citation (search report)
See references of WO 9717967A1
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 9717967 A1 19970522; AU 710337 B2 19990916; AU 7734396 A 19970605; EP 0865280 A1 19980923; JP H11507395 A 19990629
DOCDB simple family (application)
US 9618321 W 19961112; AU 7734396 A 19961112; EP 96940465 A 19961112; JP 51909197 A 19961112